SIGLEC9 and lung cancer: SIGLEC9 upregulation was related to poorer overall survival (OS) and 5-year OS in lung cancer, esophageal carcinoma, and low-grade gliomas (LGGs), while the opposite results were obtained for adenoid cystic carcinoma (ACC).